IgG4-related disease administered dupilumab: case series and review of the literature

Dupilumab (DUP) is a monoclonal antibody that acts on the interleukin (IL)-4 receptor alpha, which inhibits IL-4 and IL-13 signalling and is approved for type 2 inflammatory diseases such as asthma, chronic rhinosinusitis with nasal polyposis and atopic dermatitis; however, the efficacy of DUP to Ig...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanda, Masatoshi, Kamekura, Ryuta, Sugawara, Masanari, Nagahata, Ken, Suzuki, Chisako, Takano, Kenichi, Takahashi, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Miscellaneous
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008221/
https://www.ncbi.nlm.nih.gov/pubmed/36894196
http://dx.doi.org/10.1136/rmdopen-2023-003026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008221/
https://www.ncbi.nlm.nih.gov/pubmed/36894196
http://dx.doi.org/10.1136/rmdopen-2023-003026

Ejemplares similares